Literature DB >> 1594819

Applications of crude incidence curves.

E L Korn1, F J Dorey.   

Abstract

Crude incidence curves display the cumulative number of failures of interest as a function of time. With competing causes of failure, they are distinct from cause-specific incidence curves that treat secondary types of failures as censored observations. After briefly reviewing their definition and estimation, we present five applications of crude incidence curves to show their utility in a broad range of studies. In some of these applications it is helpful to model survival-time distributions with use of two different time metameters, for example, time from diagnosis and age of the patient. We describe how one can incorporate published vital statistics into the models when secondary types of failure correspond to common causes of death.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1594819     DOI: 10.1002/sim.4780110611

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  28 in total

1.  Assessing treatment benefit with competing risks not affected by the randomized treatment.

Authors:  Edward L Korn; James J Dignam; Boris Freidlin
Journal:  Stat Med       Date:  2014-11-03       Impact factor: 2.373

2.  The use and interpretation of competing risks regression models.

Authors:  James J Dignam; Qiang Zhang; Masha Kocherginsky
Journal:  Clin Cancer Res       Date:  2012-01-26       Impact factor: 12.531

3.  Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996-2009.

Authors:  Anne M Butler; Andrew F Olshan; Abhijit V Kshirsagar; Jessie K Edwards; Matthew E Nielsen; Stephanie B Wheeler; M Alan Brookhart
Journal:  Am J Kidney Dis       Date:  2015-02-07       Impact factor: 8.860

Review 4.  Statistical methods for dependent competing risks.

Authors:  M L Moeschberger; J P Klein
Journal:  Lifetime Data Anal       Date:  1995       Impact factor: 1.588

5.  Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003).

Authors:  Christine H Chung; James J Dignam; M Elizabeth Hammond; Alexander C Klimowicz; Stephanie K Petrillo; Anthony Magliocco; Richard Jordan; Andy Trotti; Sharon Spencer; Jay S Cooper; Quynh-Thu Le; K Kian Ang
Journal:  J Clin Oncol       Date:  2011-02-28       Impact factor: 44.544

6.  Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study.

Authors:  Joan L Walker; Marion R Piedmonte; Nick M Spirtos; Scott M Eisenkop; John B Schlaerth; Robert S Mannel; Richard Barakat; Michael L Pearl; Sudarshan K Sharma
Journal:  J Clin Oncol       Date:  2012-01-30       Impact factor: 44.544

7.  Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer.

Authors:  James J Dignam; Kelly Wieand; Karen A Johnson; Bernard Fisher; Lei Xu; Eleftherios P Mamounas
Journal:  J Natl Cancer Inst       Date:  2003-10-01       Impact factor: 13.506

8.  A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.

Authors:  Aaron H Wolfson; Mark F Brady; Thomas Rocereto; Robert S Mannel; Yi-Chun Lee; Robert J Futoran; David E Cohn; Olga B Ioffe
Journal:  Gynecol Oncol       Date:  2007-09-05       Impact factor: 5.482

9.  Competing event risk stratification may improve the design and efficiency of clinical trials: secondary analysis of SWOG 8794.

Authors:  Kaveh Zakeri; Brent S Rose; Sachin Gulaya; Anthony V D'Amico; Loren K Mell
Journal:  Contemp Clin Trials       Date:  2012-10-11       Impact factor: 2.226

10.  Competing risk regression models for epidemiologic data.

Authors:  Bryan Lau; Stephen R Cole; Stephen J Gange
Journal:  Am J Epidemiol       Date:  2009-06-03       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.